Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Under provisions of the Affordable Care Act, insurers must cover costs related to PrEP.
Currently, fewer than 1 in 10 women eligible for HIV prevention medications are taking them.
Many women could benefit from pre-exposure prophylaxis to prevent HIV.
Previous research has shown low rates of use of HIV prevention products, but the tide could be turning.
However, the benefit would be less evident in Georgia, the state with the highest lifetime risk of acquiring HIV.
HIV, hepatitis and LGBTQ advocates lead the charge. Plus, a study suggests that long-acting injectable PrEP isn’t cost effective.
The Food and Drug Administration approved Apretude as the first long-acting injectable option for pre-exposure prophylaxis.
New HIV treatment guidelines boost TAF and dolutegravir but warn about Trogarzo and advise against Cabenuva for pregnant people.
Two bills in Congress will establish PrEP programs to prevent HIV. They’re needed to address racial and ethnic disparities in the epidemic.
This quick reference chart compares the available options for pre-exposure prophylaxis (PrEP) for the preve...
Starting today, the CDC recommends that clinicians prescribe pre-exposure prophylaxis to anyone who asks for it.
Long-acting injections given every two months could soon offer a new option for HIV pre-exposure prophylaxis.
Injections of cabotegravir given once every two months may work even better than daily pills for HIV prevention.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.